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Abstract: Hereditary Angioedema (HAE) is a rare disease and for
this reason proper diagnosis and appropriate therapy are often
unknown or not available for physicians and other health care
providers. For this reason we convened a group of specialists that
focus upon HAE from around the world to develop not only a con-
sensus on diagnosis and management of HAE, but to also provide
evidence based grades, strength of evidence and classiﬁcation for the
consensus. Since both consensus and evidence grading were adhered
to the document meets criteria as a guideline. The outcome of the
guideline is to improve diagnosis and management of patients with
HAE throughout the world and to help initiate uniform care and
availability of therapies to all with the diagnosis no matter where the
residence of the individual with HAE exists.
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Hereditary angioedema (HAE) is a global health
problem, and evidence-based guideline recommendations
are needed to inform and guide clinical decision makers.
This document presents the ﬁrst global guideline for the
management of HAE and was developed by the World
Allergy Organization (WAO) HAE International Alliance.
The WAO guideline on the management of HAE differs from
previous consensus reports and position papers. It results
from a complete review of the underlying evidence based on
systematic and transparent assessments of the quality of this
evidence in evidence proﬁles. Furthermore, we used a Grading
of Recommendations Assessment, Development and Evalua-
tion (GRADE)–based approach for developing the recommen-
dations provided by this guideline.
1 GRADE is recommended
by the World Health Organization and takes into account that
evidence alone is insufﬁcient and that values and preferences,
clinical circumstances, and clinical expertise inevitably inﬂu-
ence decisions.
During the planning of the WAO HAE International
Guidelines, Dr Richard Lockey, then President of the WAO,
and Dr Timothy Craig, Chair of the committee, requested
nominations from WAO-Afﬁliated Allergy and Immunology
Associations to appoint members to the steering committee.
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Committee ﬁrst agreed, during a consensus meeting in
September 2010 in Gargnano, Italy, on the clinical questions
to be addressed by the guideline. Working groups were
assigned to review and assess the evidence available to
answer these questions.
2
Based on the assessment of the evidence, the panel
members, in a consensus conference at the European
Academy of Allergy and Clinical Immunology (EAACI)
Annual Meeting in June 2011 in Istanbul, Turkey, devel-
oped recommendations. Strong recommendations indicate
that most physicians would want and only few would not
want the recommended course of action, that adherence to
the recommendation in clinical practice could be used as
a quality criterion, and that the recommendation can be
adapted as policy in most situations. Weak recommenda-
tions should be interpreted to indicate that the majority of
physicians would want, but that many would not want, the
suggested course of action, that in clinical practice, different
choices will be appropriate for individual patients, and that
policy making will require substantial debate and the
involvement of various stakeholders. Understanding the
interpretation of these 2 gradesdeither strong or conditio-
naldof the strength of recommendations is essential for
clinical decision making.
A second uniqueness of this document is that world
involvement was ensured by requesting nominations for
the committee from afﬁliated Allergy and Immunology
Associations of the WAO. This worldwide approach was
necessary to have global appeal and opinion in the care of
HAE. Even though therapies are limited in certain areas of
the world, it is hoped that this consensus will help justify
the use of therapies for all patients. Furthermore, this
consensus hopefully will assist clinicians, medical associ-
ations, HAE patient associations, and national medical
communities to appeal for the appropriate therapies for all
patients with HAE.
The goal of this guideline is to provide clinicians and
their patients with guidance for rational decisions in the
management of HAE types 1 and 2 (HAE-1/2). To this end,
20 recommendations [numbered and given in framed boxes]
were developed. The key clinical questions covered by these
recommendations are (1) How should HAE be deﬁned and
classiﬁed? (2) How should HAE be diagnosed? (3) Should
HAE-1/2 patients receive prophylactic and/or on-demand
treatment and what treatment options should be used? (4)
Should HAE-1/2 management be different for special
HAE-1/2 patient groups such as pregnant/lactating women
or children? and (5) Should HAE-1/2 management incor-
porate self-administration of therapies and patient support
measures?
MATERIALS AND METHODS
Nomination of Experts
Individuals were nominated to the expert panel and
group of authors by the WAO and afﬁliated associations.
At least one of the following criteria had to be fulﬁlled:
(1) extensive clinical experience in the treatment of HAE,
(2) relevant publications in the ﬁeld of HAE, and (3)
relevant experience in evidence-based medicine. Emphasis
w a sp l a c e do ns e l e c t i n gar e p r esentative panel of experts
from throughout the world to ensure global expertise and
consensus. In addition, the WAO requested a representative
from the international HAE patient association (HAEi) to
participate as a steering committee member. Nine patient
representatives were nominated by HAEi and participated
in the process (selection of key questions and consensus
conference).
2
Support for the Consensus
The consensus conference held in Gargnano del
Garda, Italy, from September 26 to 29, 2010, hosted 58
experienced HAE expert physicians from 17 countries
(listed as Hereditary Angioedema International Working
Group). In addition, there were 22 representatives of the 5
pharmaceutical companies producing drugs for HAE. The
latter were invited to provide additional data on their
products. These representatives did not take part in any
voting procedures.
2
Four of the 5 pharmaceutical companies producing
drugs for HAE (CSL Behring, Marburg, Germany; Dyax,
Cambridge, MA; Pharming, Leiden, the Netherlands;
Shire, Dublin, Ireland; and ViroPharma, Exton, PA) pro-
vided the ﬁnancial support for the document and required
meetings. Pharming did not have a product on the market
at the time of the initiation of this endeavor. No company
was present during the meetings, had input into the manuscript,
or allowed to provide feedback. The pharmaceutical com-
panies were not allowed to view the document before
publication. This was essential to prevent bias and real or
perceived commercial inﬂuence on the outcomes. All
participants were required to submit conﬂict of interest
statements to participate on the committee and were also
required to submit conﬂict of interest documents with the
manuscript.
Selection of Key Questions
At the 2010 Gargnano Consensus Conference, the
guideline steering committee selected key questions by means
of majority vote. Expert panel members were assigned to topic-
focused working groups. These working groups performed
targeted literature searches and used those results together with
the outcome of the 2010 Gargnano Consensus Conference–
developed guideline recommendations. These recommendations
were then discussed and ﬁnalized during the 2011 Istanbul Con-
sensus Conference. The working groups determined that for
many of the key questions in HAE management, little or no
evidence is available to base answers and recommendations on.
The expert panel recognizes this current limitation.
Literature Search
To ﬁnd relevant literature for the identiﬁed key ques-
tions, we performed systematic searches of the MEDLINE
and COCHRANE databases. Our search covered the period
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strategies were as follows:
Results of search 8: Munch and Weeke,
3 Lewis,
4 Gluszko
et al,
5 Cicardi et al,
6 Waytes et al,
7 Cicardi et al,
8 Goring et al,
9
Kunschak et al,
10 Farkas et al,
11 Bork and Barnstedt,
12 Gompels
et al,
13 Weiler et al,
14 Szeplaki et al,
15 van Doorn et al,
16
Bas et al,
17 Bork et al,
18 O t te ta l ,
19 Schneider et al,
20 Varga
et al,
21 Visy et al,
22 Birjmohun et al,
23 Cedzynski et al,
24 Szegedi
et al,
25 Craig et al,
26 Kreuz et al,
27 Bas et al,
28 Bernstein et al,
29
Cicardi et al,
30 Cicardi et al,
31 Craig et al,
32 Levy et al,
33 Zuraw
et al,
34 Zuraw et al.
35
Reasons for excluding a study from the 33 hits of search
8 were as follows: (1) no original phase 3 (or 4) trials for acute
treatment of HAE, (2) no human data, (3) no clinical data, and
(4) not dealing with the management of HAE/not suitable to
answer selected key questions. The bibliographic information
of the included trials was transferred to an endnote database,
and full-text publications were obtained. Further analysis was
done using a standardized Literature Evaluation Form. Eval-
uation was done by 2 independent assessors, who had been
trained in using the Literature Evaluation Form. Any discrep-
ancies were reviewed by a third assessor and resolved through
discussion.
Using the Literature Evaluation Form (Fig. 1), the
methodologists evaluated a total of 33 studies. Of these stud-
ies, 8 phase 3 trials were ultimately included.
7,10,26,30,31,33–35
To further facilitate the evidence review, we also searched
for meta-analyses, guidelines, and consensus statements.
Results of search 12: Bissler et al,
36 Zhang et al,
37
Bowen et al,
38 Bowen et al,
39 Bracho,
40 Chinen and
Shearer,
41 Gompels et al,
42 Bowen et al,
43 Bowen,
44 Bowen
et al,
45 Bowen et al,
46 and Longhurst et al.
47
Four out of 12 (search 12) identiﬁed international
consensus articles were considered relevant and were distributed
to the group as a basis for discussion and adaptation.
39,43,46,47
To answer selected key questions, the search was
further speciﬁed to the following:
Results of search 13: Cicardi et al,
8 Farkas et al,
11 Szeplaki
et al,
15 Ott et al,
19 Birjmohun et al,
23 and Szegedi et al.
25
Reasons for excluding a study were as follows: (1) no
original data, (2) no human data, (3) no clinical data, and
(4) not dealing with the management of HAE/not suitable to
answer selected key questions. After screening, all hits
fulﬁlled the inclusion criteria.
Grade of Evidence
Each trial included in the guideline was evaluated with
regard to its methodological quality and assigned a grade of
evidence according to the grading system used in previous
guidelines: A, Randomized, double-blind, clinical trial of high
quality (eg, sample size calculation, ﬂow chart of patient
inclusion, intention-to-treat analysis, sufﬁcient sample size); B,
Randomized clinical trial of lesser quality (eg, only single blind
and limited sample size: at least 15 patients per study arm); C,
Comparative trial with severe methodological limitations (eg,
not blinded, very small sample size, and no randomization)
or large retrospective observational studies; D, Adapted from
existing consensus document or statement based on expert opin-
ion voting during consensus conference.
Strength of Recommendation
To avoid any potential confusion, standardized phrases
were used to express the strength of a recommendation
throughout the guideline. The following GRADE deﬁnitions
for recommendation strength were used: Strong recommenda-
tions indicate that the desirable effects of an intervention
clearly outweigh the undesirable effects. When the trade-offs
were less certain, a “conditional” strength of recommendations
was assigned. In case of strong expert support, a strong rec-
ommendation was applied even in cases where only very little
evidence was available.
Classiﬁcation of Evidence
A level of evidence was assigned to each clinical question
based on the available trials/articles. The following levels of
evidence for relevant key questions were applied; low levels
of evidence indicate a need for more high-quality research in
these areas.
Step Search Term Hits
9 Limit 7 to “Meta-Analysis” 0
10 Limit 7 to “Practice Guideline” 0
11 Limit 7 to “Guideline” 0
12 7 AND “consensus” 12
Step Search Term Hits
13 8 "AND danazol[ti] OR stanozolo[ti] OR tibolone[ti] 6
Step Search Term Hits
1 “hereditary angioedema” 832
2 “hereditary angiooedema” 10
3 “hereditary angio-oedema” 85
4 “hereditary angioneurotic edema” 292
5 “hereditary angioneurotic oedema” 91
6 1 OR 2 OR 3 OR 4 OR 5 1275
7 limit 6 to yr¼“1985 -Current” 894
8 limit 7 to “Clinical Trial” 33
Grade of
Evidence
Number of Trials Authors
A 6 Craig et al,
26 Cicardi et al,
30
Cicardi et al,
31 Levy et al,
33
Zuraw et al,
34 Zuraw et al
35
B 1 Kunschak et al
10
C 7 Waytes et al,
7 Cicardi et al,
8
Farkas et al,
11 Szeplaki
et al,
15 Ott et al,
19
Birjmohun et al,
23 Szegedi
et al
25
D 4 Bowen et al,
39,43,46 Longhurst
et al
47
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Based on the assessment of the evidence, the panel
members, during a consensus conference in June 2011 in
Istanbul, Turkey, the expert group developed recommenda-
tions and agreed on the strength of these recommendations.
International experts in HAE (the review board consultation
group) were requested to review the Guidelines and provide
feedback, suggestions and areas of dispute with the authors.
The guidelines were then reviewed by the ofﬁcial body of
the WAO composed of the regional allergy societies and the
FIGURE 1. Literature evaluation form.
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gates as the international guideline for HAE.
DEFINITIONS, NOMENCLATURE,
AND CLASSIFICATION
Angioedema is deﬁned as a vascular reaction of the deep
dermis or subcutaneous/submucosal tissues with localized dila-
tation and increased permeability of blood vessels resulting in
tissue swelling.
48–52 Angioedema can be mediated by bradyki-
nin or mast cell mediators including histamine (Table 1).
53
Bradykinin-mediated angioedema can occur either on a heredi-
tary or acquired basis, due to a deﬁciency/defect of C1 inhibitor
(C1-INH) or not (Table 1).
54–56 Three forms of HAE have been
deﬁned: (1) HAE due to C1-INH deﬁciency (type 1 HAE,
HAE-1), characterized by low antigenic and functional C1-
INH levels; (2) HAE due to C1-INH dysfunction (type 2
HAE, HAE-2), characterized by normal (or elevated) antigenic
but low functional C1-INH levels; and (3) HAE with normal
C1-INH antigenic and functional levels (HAE-3). Acquired C1-
INH deﬁciency refers to patients with angioedema due to C1-
INH deﬁciency on an acquired basis.
39,46,57 T h e r ea r eav a r i e t y
of acquired types of angioedema not due to C1-INH deﬁciency,
and these may be bradykinin mediated [eg, angiotensin-convert-
ing enzyme inhibitor (ACE-I)-induced angioedema] or mast cell
mediator histamine mediated (eg, urticarial angioedema, ana-
phylactic angioedema).
PATHOPHYSIOLOGY
Type 1 HAE and Type 2 HAE
HAE due to C1-INH deﬁciency/defect (HAE) is a rare
disorder affecting approximately 1:50,000 individuals. It is
transmitted in an autosomal dominant genetic pattern. HAE-
1/2 are caused by a large array of different mutations of the
SERPING1 gene, which codes for C1-INH. In approximately
20%–25%, a de novo mutation of SERPING1 is responsible
for the disease.
12,58,59
C1-INH is a member of the serine protease inhibitor
(serpin) superfamily and the major inhibitor of several comple-
ment proteases (C1r, C1s, and mannose-binding lectin-associated
serine protease 1 and 2) and contact system proteases (plasma
kallikrein and coagulation factor XIIa) and a relatively minor
inhibitor of the ﬁbrinolytic protease plasmin and the coagulation
protease factor XIa.
60–62
Compelling laboratory and clinical data have conclusively
shown that bradykinin is the primary mediator of swelling in
HAE-1/2. The nanopeptide bradykinin is generated when active
plasma kallikrein cleaves high–molecular weight kininogen.
Plasma kallikrein is activated from its inactive zymogen by
the protease factor XII, and both plasma kallikrein and factor
XII are normally inhibited by C1-INH. Bradykinin has a number
of important effects on the body including normal homeostasis,
normal immune responses, inﬂammation, vascular tone, and vas-
cular permeability. The vascular permeability–increasing effect
of bradykinin in angioedema is primarily mediated through the
bradykinin B2 receptor.
63–65
Type 3 HAE
HAE with normal C1-INH (HAE-3) is a very rare disease.
The symptoms are very similar to HAE-1/2. A subset of HAE-3
patients exhibits mutations in factor XII, which are thought to
likely be responsible for the disease. The genetic abnormality of
most HAE-3 patients has not yet been deﬁned. Because of the
lack of a clear genetic deﬁnition of this type of HAE, the diag-
nosis requires a family history of angioedema. There is clinical
evidence that bradykinin also plays a major role in HAE-3.
66–68
Diagnosis
HAE-1/2 should be suspected when a patient presents
with a history of recurrent angioedema, especially if wheals
(hives) are absent. This suspicion is further substantiated when
patients report (1) a positive family history; (2) onset of sym-
ptoms in childhood/adolescence; (3) recurrent abdominal pain
attacks; (4) occurrence of upper airway edema; (5) failure to
respond to antihistamines, glucocorticoid, or epinephrine; and
(6) presence of prodromal signs or symptoms before swellings.
Suspicion of HAE-1/2 should prompt laboratory workup as the
diagnosis of HAE-1/2 requires laboratory conﬁrmation.
39,43,46,69
Recommendation 1
All patients suspected to have HAE-1/2 (ie, recurrent
angioedema in the absence of a known cause) should be
assessed for blood levels of C4, C1-INH protein, and C1-
INH function, and these tests, if abnormally low, should be
repeated to conﬁrm the diagnosis. Evidence grade: D,
strength of recommendation: strong.
TABLE 1. Classiﬁcation of Angioedema
Bradykinin-Induced AE Mast Cell Mediator–Induced AE Unknown
Mediator
C1-INH Deﬁciency/Defect C1-INH Normal
IgE
Mediated
Non-IgE
Mediated
Idiopathic
AE
Inherited Acquired Inherited Acquired Angioedema
with
anaphylaxis
Angioedema
with urticaria
d
Urticaria
HAE-1 AAE HAE-3 ACE-I dd d
HAE-2
AAE, acquired angioedema due to C1 inhibitor deﬁciency; ACE-I, angiotensin-converting enzyme-induced angioedema; AE, angioedema; HAE-1, hereditary angioedema due to
C1 inhibitor deﬁciency; HAE-2, hereditary angioedema due to C1 Inhibitor defect; HAE-3, hereditary angioedema with normal C1 inhibitor levels.
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and the C1 inhibitor functional activity are the major laboratory
tests used to diagnose HAE-1/2. In some cases, measuring the
C1q level may be useful to help exclude AAE. Abnormal results
should be conﬁrmed, and normal results may need to be
checked during an attack of angioedema. C4 is the single best
screening test, and repeating the C4 during an attack increases
the probability that a low C4 will be found. However, C4 is not
ad e ﬁnitive test because neither the sensitivity nor speciﬁcity is
absolute. There are occasional false-negative results that will be
encountered, particularly in patients who are taking anabolic
androgens. The C4 level should virtually always, however, be
reduced during an attack of angioedema. Measurement of the
activation product C4d may avoid false-negative results. False
positives can also be encountered. In summary, the C4 level is
useful for screening but cannot be relied upon to conﬁrm or
exclude a diagnosis of HAE-1/2.
13,70,71
In a patient with a high index of suspicion for HAE, the
C1-INH antigenic level and/or functional activity should be
directly measured. The C1-INH antigenic level is low in HAE-1
and acquired C1-INH deﬁciency patients but is normal in HAE-2
patients. The C1-INH functional activity is low in HAE-1 and
HAE-2 and acquired C1-INH deﬁciency patients.
13,42,72
In rare patients, sequencing of the SERPING1 gene can
be done to pursue diagnosis of HAE-1/2; sequencing of factor
XII genes can help to diagnose HAE-3; however, it is rare that
this approach is needed. Complement C3 levels are expected
to be normal, and testing CH50 is not useful. Many patients
with acquired C1-INH deﬁciency have autoantibodies that
recognize and inactivate C1-INH.
73–75
Differential Diagnosis
The differential diagnoses of HAE-1/2 include HAE-3 (ie,
HAE with normal C1-INH), acquired C1-INH deﬁciency
(AAE), ACE-induced angioedema, mast cell mediator–induced
angioedema (eg, chronic spontaneous urticaria, allergic angio-
edema), and idiopathic angioedema (Fig. 2). Because the path-
ophysiology and the treatment of these diseases are different
than those of HAE-1/2, it is important to determine the exact
diagnosis so that appropriate therapy for the speciﬁct y p eo f
angioedema the patient is manifesting can be used.
39,43,46,53,76
Mast cell mediator–induced angioedema is frequently
associated with wheal- and ﬂare-type skin reactions (hives),
ie, in patients with chronic urticaria, and is more common than
bradykinin-induced angioedema. Antihistamines, epinephrine,
and glucocorticosteroids are effective in treating mast cell
mediator–induced angioedema, but higher than standard doses
of antihistamines are frequently necessary. Because mast cell
mediator–induced angioedema is far more common than
HAE-1/2, therapy with antihistamines and, if necessary, with
epinephrine and glucocorticosteroids, is indicated when the
diagnosis is not yet determined and the history seems to be
inconsistent with HAE.
77,78
HAE-3 is similar to HAE-1/2 but shows differences in
the underlying pathophysiological pathways. Because of this,
the management may be different and it should not be assumed
that HAE-3 will respond similarly to available therapies
designed to treat HAE-1/2.
66,67,79 Angioedema may be second-
ary to medications and frequently complicates the use of ACE
inhibitors (ACE-I). One in 200 to 1000 patients treated with
ACE-I will develop angioedema. Angioedema from ACE-I is
bradykinin-induced but has a different mechanism than HAE-
1/2. Because of the difference in pathophysiology, response to
medications used for HAE-1 and HAE-2 cannot be assumed to
work in ACE-I angioedema.
Angioedema due to acquired C1-INH deﬁciency is
a rare disease that presents similarly to HAE. Differences
include onset in later age, often underlying diseases such as
lymphoma or monoclonal gammopathy, occasional constitu-
tional symptoms, and depressed C1 q-r-s levels. C1q level
measurements should be obtained to investigate patients
for AAE-C1-INH, especially with new onset of angioedema
after the age of 40 years.
80–82
THERAPY OF HAE-1/2
On-Demand Treatment
Recommendation 2
All attacks that result in debilitation/dysfunction and/
or involve the face, the neck, or the abdomen should be
considered for on-demand treatment. Treatment of attacks
affecting the upper airways is mandatory. Evidence grade:
D, strength of recommendation: strong.
Recommendation 3
We recommend that attacks are treated as early as
possible. Evidence grade: D, strength of recommendation:
strong.
Attacks of the upper airways can result in asphyxiation.
Abdominal attacks are painful and debilitating. Peripheral attacks,
for example, of hands or feet, result in impaired function. All of
these consequences of HAE-1/2 attacks can be minimized by on-
demand treatment. Evidence suggests that early treatment is
advantageous. Every patient with HAE-1/2 should be considered
for home therapy and self-administration training, once the
diagnosis of C1-INH deﬁciency is conﬁrmed.
47,83–86
Recommendation 4
We recommend that HAE attacks are treated with
C1-INH, ecallantide, or icatibant. Evidence grade: A,
strength of recommendation: strong.
If these drugs are not available, attacks should be
treated with solvent detergent-treated plasma (SDP). If SDP is
not available, then attacks should be treated with frozen
plasma (where safe supply is available). Evidence grade: D,
strength of recommendation: strong (Fig. 3; Table 3).
Recommendation 5
We recommend that intubation or tracheotomy is
considered early in progressive upper airway edema.
Evidence grade: D, strength of recommendation: strong.
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We recommend that patients with attacks receive
adjuvant therapy when indicated (pain management,
intravenous ﬂuids, and supportive care), but speciﬁc
therapies should be used without delay when indicated.
Evidence grade: D, strength of recommendation: strong.
Recommendation 7
We recommend that oral antiﬁbrinolytics are not to
be used as on-demand treatment. Evidence grade: A,
strength of recommendation: strong.
Treatment With C1-INH Concentrate
Treatment with C1-INH concentrate eliminates the
underlying cause of HAE-1/2 by replacing the deﬁcient protein.
Exogenous C1-INH concentrate acts on the same targets as
endogenous C1-INH and inactivates C1r, C1s, and mannose-
binding lectin-associated serine proteases in the complement
system and factor XII, factor XI, and thrombin in the
coagulation cascade and kallikrein in the contact system
and tissue-type plasminogen activator and plasmin in the
ﬁbrinolytic system. Treatment results in an increase of the
plasma levels of the C1-INH and helps to regulate activation of
all cascade systems involved in the production of bradykinin
released during attacks.
7,10,26,32,35
Plasma-Derived C1-INH
Plasma-derived C1-INH (pdC1-INH) is obtained from
human blood. One unit of pdC1-INH is equivalent to the
C1-INH content of 1 mL of human plasma (270 mg/L).
Three pdC1-INH concentrates are approved for
on-demand treatment of HAE-1/2 in Europe: Berinert (CSL
Behring), Cetor (Sanquin, Amsterdam, the Netherlands), and
Cinryze (Viropharma) and one in the United States: (Berinert;
CSL Behring). Berinert and/or Cinryze are also available in
many other countries, for example, both drugs are registered
for use in Australia.
Berinert [20 U/kg body weight slowly intravenous (IV)]
is approved for the treatment of all types of attacks of HAE-1/
2 in adults, children, and neonates. Cetor/Cinryze (1000 U
slowly IV) are indicated for all types of attacks for ages 12
years and over.
pdC1-INH is obtained by separating C1-INH from
cryodepleted human plasma by adsorption and precipitation,
puriﬁcation, pasteurization, and nanoﬁltration. The plasma half-
life of pdC1-INH is longer than 24 hours (Berinert: 32–47
hours; Cetor/Cinryze: 48 6 10 hours). All pdC1-INH prod-
ucts are comparable in efﬁcacy and adverse effect proﬁle.
The safety and tolerability of pdC1-INH are good, and few
adverse events have been reported. The risk of allergic
reactions is negligible. Modern pdC1-INH use has not been
associated with transmission of hepatitis B or C or human
immunodeﬁciency viruses.
29,87,88
Thrombotic events have occurred in off-label use in pre-
mature neonates receiving extremely high doses of pdC1-INH
(500 U/kg body weight) to relieve capillary leak syndrome.
There are no known interactions with other medicinal products.
FIGURE 2. Diagnostic algorithm for
HAE-1/2. AAE = Acquired angioedema
due to C1-INH deﬁciency.
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seen increasing doses required to prevent attacks when C1-INH
is used regularly for prophylaxis.
89–91
Recombinant C1-INH
The mode of action of recombinant human C1-INH
(rhC1-INH) is identical to that of pdC1-INH. The only rhC1-
INH available is Ruconest (Pharming). RhC1-INH (50 U/kg
body weight slowly IV) is indicated for the on-demand
treatment of all types of HAE attacks in adults. It is expressed
in the mammary gland of transgenic rabbits and is obtained
from their breast milk. One unit of rhC1-INH corresponds to
the mean quantity of C1-INH present in 1 mL fresh normal
plasma. Its half-life is 3 hours. Before initiating treatment
with rhC1-INH, patients must be tested for the presence of
immunoglobulin E (IgE) antibodies against rabbit allergens
using a validated test for IgE antibodies against rabbit
epithelium (dander). IgE antibody testing should be repeated
annually or after 10 treatments, whichever occurs ﬁrst,
although sensitization or induction of signiﬁcant rabbit or
rhC1-INH–related antibodies has not been seen to date. It
must not be used in patients with a preexisting known or
suspected allergy to rabbit dander. The most common side
effect of rhC1-INH (seen in 1–10 patients out of 100) is
headache and is unlikely related to the drug. Transmission
of human viruses is not a concern.
34,92
Treatment With Kallikrein Inhibitor
Inhibition of kallikrein activity inhibits the cleavage of
high–molecular weight kininogen to bradykinin and inhibits
edema progression in HAE-1/2 attacks (Fig. 2). The only com-
mercial kallikrein inhibitor is ecallantide (Kalbitor; Dyax).
Ecallantide (30 mg, subcutaneous (s.c.) injection) is indicated
for the on-demand treatment of all types of HAE attacks in
patients 16 and older. Ecallantide is a 60–amino acid recombi-
nant protein produced by expression in the yeast Pichia pas-
toris, and has a plasma half-life of 2 hours. Because the size of
the peptide and that it is foreign antibodies from both IgG and
IgE classes have been detected. In addition antibodies have
been demostrated to the yeast that is used in developing
ecallantide.
31,33,93
Treatment With Bradykinin Receptor Antagonist
Bradykinin induces angioedema by activating bradyki-
nin B2 receptors, and it is blocked by the B2 receptor
antagonist, Icatibant, which prevents binding as a competitive
antagonist. Icatibant (Firazyr; Shire) is a 10–amino acid syn-
thetic peptide, which is a speciﬁc and selective competitive
antagonist of the bradykinin B2 receptor and the only com-
mercial B2 receptor antagonist. Icatibant (30 mg, s.c.) is indi-
cated for the on-demand treatment of all types of HAE attacks
in adults. It has a plasma half-life of 1 to 2 hours. The safety
and tolerability of Firazyr are good. Transient local injection
site reactions (erythema, wheal, pruritus, and burning sensa-
tion) occur in almost 100% of patients. Allergic reactions
have not been reported.
18,30,94
Recommendation 8
We recommend that all patients should have on-
demand treatment for 2 attacks. Evidence grade: D, strength
of recommendation: strong.
Recommendation 9
We recommend that all patients should carry their
on-demand treatment at all times. Evidence grade: D,
strength of recommendation: strong.
Short-term/Preprocedural Prophylaxis
Physical trauma and emotional stress are inevitable
consequences of surgery and are well-recognized precipitants
of HAE-1/2 attacks. Swellings associated with surgery
usually occur 4 to 30 hours after the event. Because swellings
usually occur near the site of surgical trauma, dental surgery
is considered particularly high risk because of its association
with upper airway edema.
39,42,43,46,76,95
Despite the perceived beneﬁts of preprocedural pro-
phylaxis, evidence for its efﬁcacy is lacking. Case reports and
series suggest that despite prophylaxis, swellings may occur
even after relatively minor procedures. However, several
reports document a reduction in the incidence of swelling for
both adults and children with prophylaxis. The decision to
give prophylaxis before a procedure depends on the patient’s
personal history and the likely risk associated with the pro-
cedure. A history of frequent swellings; swellings after a sim-
ilar procedure, dental, or other intraoral surgery; the need for
intubation; or more invasive procedures favor preprocedural
prophylaxis. Short-term prophylaxis should also be consid-
ered to cover periods of high risk for attacks when there is
either increased likelihood of attack or increased consequence
of attack (ie, stressful periods, examinations, or similar).
For lower risk procedures or where safe on-demand
agents are available, prophylaxis may be omitted. The patient
should be aware of the risk and have a management plan and
on-demand treatment for attacks. Where available, 2 doses of
C1-INH concentrate, ecallantide, or icatibant, should be
immediately accessible.
11,95–99
Recommendation 10
The administration of short-term prophylaxis should
be considered before surgeries, especially dental/intraoral
surgery, where endotracheal intubation is required, where
upper airway or pharynx is manipulated, and before
bronchoscopy or endoscopy. Evidence grade: D, strength
of recommendation: strong.
For short-term/preprocedural prophylaxis, C1-INH con-
centrate should be used (dose yet to be fully investigated with
recommendations varying from 10 to 20 U/kg body weight or
1000 U), 1 to 6 hours before procedure.
Prophylactic C1-INH concentrate dosing requires further
studies. Even at 1000 units, breakthrough attacks occurred,
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vent attacks. SDP can be used if C1-INH concentrate is not
available.
Androgens (danazol, stanozolol) may be used for short-
term/preprocedural prophylaxis when the surgery-related risk
is relatively low and when C1-INH concentrate is not
available. Advantages are ease of use, good tolerability for
most, including children, and low cost. Disadvantages are
perceived inferior efﬁcacy to C1-INH concentrate (although
evidence is lacking), use in case of elective surgery only, side
effects, and unsuitability for pregnant (except last trimester)
or breastfeeding women. Side effects in short-term use may
include menstrual disturbance, vaginal dryness or irritation,
and emotional lability. Beyond pregnancy testing, other blood
tests or safety monitoring are not necessary. Very frequent
short courses may lead to side effects associated with long-
term use. For short-term/preprocedural prophylaxis, andro-
gens are used for 5 days before and 2 to 5 days post event
(danazol is used at 2.5–10 mg$kg21$d21, maximum 600 mg;
stanozolol is used at 4–6 mg/d).
Tranexamic acid (TA) has been used for short-term/
preprocedural prophylaxis in the past, the recommended dose
for oral TA (not fully established) is 25 mg/kg 2 to 3 times
daily with maximum 3 to 6 g daily. The efﬁcacy in suppressing
breakthrough attacks seems to be low.
39,42,43,46,76
Long-term Prophylaxis of HAE-1/2
Long-term prophylaxis of HAE refers to the use of
regular medication to prevent episodes of angioedema in
patients with conﬁrmed HAE-1/2. Long-term prophylaxis
should be considered in all severely symptomatic HAE-1/2
patients taking into consideration the severity of disease,
frequency of attacks, patient’s quality of life, availability of
resources, and failure to achieve adequate control by appro-
priate on-demand therapy. C1-INH concentrate or androgens
can be used for long-term prophylaxis and the decision to use
one over the other should depend upon contraindications,
adverse events, risk factors for adverse effects, tolerance,
response to intervention, and dose required to control attacks.
None of the current prophylactic modalities are capable of
preventing upper airway edema with certainty.
39,42,43,46,76
pdC1-INH can be used for the prevention of HAE
attacks. The food and Drug Administration (FDA, USA) and
the European Medicines Agency (EMA, EU) approved the
prophylactic use of pdC1-INH (Cinryze).
35
Dosing should be twice a week based upon the half-life
of C1-INH. Dose and/or frequency may need adjustment for
optimum control. On-demand therapy (C1-INH concentrate,
ecallantide, or icatibant) should be available for all patients on
prophylaxis because breakthrough attacks occur in most
patients on long-term prophylaxis.
35,99–101
Vaccination with hepatitis A and B and serologies to
these viruses and to hepatitis C, hepatitis E, human immuno-
deﬁciency virus (HIV), human T-lymphotropic virus, and
parvovirus should be done before initiation of pdC1-INH
long-term prophylaxis and once annually.
42
Long-term prophylaxis with androgen derivatives is
effective but must be regarded critically, especially on account
of their androgenic and anabolic effects. Most importantly,
androgens can cause hepatitis in a dose-dependent manner.
Therapy with androgen derivative can be hepatotoxic and can
affect serum lipid levels. Virilization is the primary compli-
cation occurring in women: menstrual disorders and even
amenorrhea, diminished libido, acne, and psychological dis-
orders such as depression and aggression are also common.
In addition, androgens are subject to numerous contraindica-
tions and show interactions with a large number of other
drugs. Careful surveillance is imperative in preventive andro-
gen therapy in HAE-1/2 given the number and severity of
adverse effects. In addition to clinical tests and examinations
and questioning of the patient, semiannual blood and urine
tests are needed, and at least once a year, an ultrasound of the
liver should be performed. The goal of prophylaxis with
androgens is the reduction of the severity and frequency of
swelling events as far as possible with a reasonable dosing
scheme.
102–110
Recommendation 11
Before the initiation of long-term prophylaxis with
androgens, measurements of complete blood count, urine
analysis, liver function tests, lipid proﬁle, assessment of
cardiac risk factors, and liver ultrasound should be
performed. While using androgens for long-term pro-
phylaxis and for 6 months after stopping therapy, complete
blood count, urine analysis, lipid panel, liver function tests,
and blood pressure should be monitored every 6 months
and an ultrasound of the liver should be done yearly to
assess for adverse events associated with androgens and
contraindications to androgens. Evidence grade: C,
strength of recommendation: strong.
The dose of androgens needed to control HAE attacks
can vary between the equivalent of 100 mg every other day
and 200 mg of danazol 3 times a day. Dosages above 200 mg
a day of danazol daily for extended periods of time are not
recommended. It is suggested to commence with a moderate
dose (eg, 100–200 mg daily) and increase or decrease on
a monthly basis depending on the frequency of episodes until
satisfactory control is reached. The response to androgens
varies considerably, and the dose required for long-term pro-
phylaxis is highly variable. For this reason, the dosage should
be adjusted to clinical response and not adjusted by laboratory
results.
39,43,46,76
Antiﬁbrinolytics are not recommended for long-term
prophylaxis because data supporting their efﬁcacy are lacking.
Nevertheless, they are widely used especially when androgens
are contraindicated and may anecdotally have some beneﬁti n
a minority of patients. Side effects are usually minor. They
include gastrointestinal upsets (can be reduced by taking the
drug with food), myalgia/creatine kinase elevation, and
a theoretical risk of thrombosis. Contraindications/precautions
include presence of thrombophilia or increased thrombotic risk
or acute thrombosis. The recommended dose of TA is 30 to
50 mg/kg daily in 2 to 3 divided doses, to a maximum of 6 g,
but dose ranging studies or blinded studies comparing with
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been performed.
30,39,43,111–114
MANAGEMENT OF HAE-1/2 IN CHILDREN
Course of Disease and Clinical Picture
HAE-1/2 symptoms may occur at any age, but attacks
usually begin during school-age years or adolescence. In 50%
of cases, the initial onset of symptoms occurs between 5 and 11
years. The gene defect is present at birth; however, symptoms
are uncommon during neonatal age or infancy. Subcutaneous
edema is the most common and the earliest symptom. Upper
airway edema rarely is an initial manifestation. Asphyxia may
ensue more rapidly in children because of smaller airway
diameter. The earliest occurrence was described in a 3-year-old
patient. Estimating the prevalence of abdominal attacks in the
pediatric population is difﬁcult, because “belly ache” is a com-
mon symptom, especially in infants. The frequency and the
severity of symptoms may increase during adolescence. The
earlier the onset of symptoms, the more severe the subsequent
course of HAE-1/2.
Erythema marginatum, as a prodromal sign, is more
frequent in the pediatric population. It has been observed in 42%
to 58% of cases, and it is often mistaken for urticaria.
115–118
Diagnosis
According to the Mendelian rules of autosomal inher-
itance, the offspring of a patient with HAE-1/2 stands a 50%
chance of inheriting the disease. Therefore, it is important to
establish the diagnosis as early as possible, ideally before the
onset of clinical manifestations.
Prenatal diagnosis of HAE-1/2 has not become wide-
spread in clinical practice. Reasons include (1) that no
mutation of the C1-INH gene can be detected in 8% to
10% of cases, (2) that identical mutations may be associated
with substantially different phenotypes, (3) that C1-INH
mutations may cause a nonfatal manageable disease in the
offspring, the severity of which cannot be predicted in
advance, and (4) recent advances in therapy have signiﬁcantly
improved quality of life of patients with HAE.
116,118,119
It is not recommended to screen children with a positive
family history (mother or father with HAE-1/2) immediately
after birth, because test results may be false.
Afterbirth,complementproteinlevelsexhibit acontinuous
increasedwhich, however, follows a nonuniform patterndand
reach the normal value by the age of 0.5 to 1 year. Complement
concentrations measured in cord blood of full-term neonates are
lower than maternal levels. Antigenic and functional C1-INH
levels correspond to 70% and 62% of adult values, respectively.
Therefore, testing under 1 year of age may not be reliable and
should be conﬁrmed after age 1.
120–122
C4 and C1-INH functional level testing is advisable in
all children with isolated angioedema of unknown etiology.
Genetic testing can prove helpful but is rarely necessary or
suggested.
Recommendation 12
Screening children for HAE-1/2 should be deferred
until the age of 12 months, and all offspring of an affected
parent should be tested. Evidence grade: D, strength of
recommendation: strong.
Therapy
Similar to adults, all pediatric HAE patients need a treat-
ment action plan and on-demand therapy.
Recommendation 13
The preferred on-demand therapy for HAE-1/2
attacks in children is pdC1-INH. Evidence grade: D,
strength of recommendation: strong.
pdC1-INH concentrate is the only approved drug for
HAE-1/2 on-demand treatment in childhood (in European
Union only, 12 years and older in the United States). Treatment
with pdC1-INH concentrate is effective in pediatric patients.
It is well tolerated and has a good safety proﬁle. Dosing of
the pdC1-INH Berinert is 20 U/kg. The pdC1-INH Cinryze
(1000 U per treatment) is licensed for the use in postpubertal
adolescents in some countries. During abdominal attacks,
parenteral ﬂuid replacement may be required in view of the
increased susceptibility of children to hypovolemia and
because extravasation into the peritoneal cavity and the
intestinal lumen can be substantial. SDP is preferred over
fresh frozen plasma (Fig. 3), but either should be used only as
second-line treatment when ﬁrst-line treatment (pdC1-INH
concentrate) is not available. Recombinant C1-INH, ecallan-
tide, and icatibant are not licensed for use in children, and
experience with these drugs in this patient population is very
limited.
116,118,119,123
Pediatric surgical interventions are less common and
shorter in duration although dental procedures should be
considered for preprocedural prophylaxis. pdC1-INH is the
ﬁrst-line short-term prophylactic option, but short courses of
androgens can be used as second line in the event C1-INH is
not available. With either option, on-demand therapy should be
available because short-term prophylaxis is not 100% effective.
The majority of children do not require long-term
prophylaxis. During this period of life, on-demand therapy of
attacks is preferable. The indications for long-term prophylaxis
FIGURE 3. Treatment algorithm for HAE-1/2.
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39,43,46,76,123 The
preferred therapy for long-term prophylaxis is pdC1-INH
with dose requiring further study. Routine prophylactic treat-
ment of postpubertal adolescents with Cinryze (1000 U every
3 or 4 days) is licensed in many countries and Cetor in the
Netherlands.
123
When pdC1-INH is not available for long-term pro-
phylaxis, antiﬁbrinolytics (20–40 mg/kg) are preferred to andro-
gens because of their better safety proﬁle; however, efﬁcacy is
questioned by many and data are not available supporting its
use. Epsilon aminocaproic acid is less well tolerated than TA.
Androgens are not recommended for long-term prophylaxis in
prepubertal children, but long-term use in children has been
reported, and in some cases, the beneﬁts may outweigh the
risks. Androgens (dosing danazol equivalent 2.5 mg/kg per
day; 50 mg/d initial dose with subsequent reduction of the
dosage interval to every other day or every third day; maximum
single dose is 200 mg over 10 years of age) result in masculin-
ization and hypogonadism in boys and menstruation irregular-
ities in girls. Unfavorable effects on mental functions and
behavior are common. Reduction in ultimate body height
may occur owing to the premature closure of epiphyseal growth
plates. Adverse reactions can be minimized by administering
the lowest effective dose.
Although prepubertal children typically experience
fewer attacks than adolescents and adults, some have frequent
attacks that disrupt education and family life, and long-term
prophylaxis can be beneﬁcial in these cases. Long-term
prophylaxis with attenuated androgens is not recommended,
and TA may be of limited beneﬁt. pdC1-INH is effective for
treatment of children, and home on-demand therapy has been
used successfully in this age group.
39,43,46,76,123
Primary Prevention
The incidence of trigger factors differs slightly among
pediatric and adult patients. Infections and mechanical trauma
are more common trigger factors during childhood. Compul-
sory and recommended vaccinations for children are safe,
and the prevention of infections may reduce the frequency
of edematous attacks. Medicinal products, which can cause
edema as an adverse effect, are less frequently used in
children. Treatment with ACE-I is less often necessary during
childhood; however, early initiation of oral estrogen contain-
ing contraceptives is increasingly common and may trigger
attacks.
124–126
Other Management Considerations
Providing the patient and family with appropriate infor-
mation is indispensable to support them to adopt a suitable
lifestyle and to avoid severe complications. Pedagogues,
teachers, and health care personnel responsible for the child at
kindergarten or school should receive written information on
the disease. pdC1-INH for emergency use should be available
at home, school, and for travel including school ﬁeld trips.
Vaccination for hepatitis B and A should be done if not part of
a country’s routine vaccine recommendation.
116,118
MANAGEMENT OF HAE-1/2 DURING
PREGNANCY AND LACTATION
Course of Disease and Clinical Picture
The anatomical and physiologicaldprimarily hormonald
changes of pregnancy may inﬂuence the manifestations of HAE
and interfere with the diagnosis and the treatment of HAE.
Pregnancy can either mitigate or aggravate HAE; alternatively,
it may have no impact whatsoever. Infrequently, the manifesta-
tions of HAE ﬁrst occur during pregnancy. Attack frequency
observed during previous pregnancies is not predictive of
HAE events during any subsequent pregnancy. Pregnant
HAE-1/2 patients require vigilant care and meticulous monitor-
ing by an HAE expert. Patients should be managed in close
cooperation by professionals from relevant medical specialties.
Labor and delivery themselves only rarely induce an attack,
which may occur either during labor or within 48 hours of
delivery. Close follow-up is recommended for at least 72 hours
postpartum after uncomplicated vaginal delivery. Breastfeeding
may be associated with an increased number of maternal edem-
atous attacks, with abdominal symptoms and facial edema, but
is still recommended.
87,114,127–131
Diagnosis
Special procedures are required for diagnosing HAE-1/2
during pregnancy. The plasma level of C1-INH decreases
during pregnancy, and it returns to normal after delivery.
Therefore, repeated measurements of C1-INH levels are
necessary after childbirth to conﬁrm the diagnosis of HAE.
114
Therapy
Recommendation 14
During pregnancy and lactation, pdC1-INH is the
preferred therapy. Evidence grade: D, strength of recom-
mendation: strong.
pdC1-INH is recommended as ﬁrst-line therapy for
pregnant or breast-feeding HAE-1/2 patients as it is safe and
effective. No published experience is available with recombinant
C1-INH, ecallantide, and icatibant. SDP may be used when
pdC1-INH is not available and fresh frozen plasma when SDP is
not available (Fig. 3).
114,117
Short-term prophylaxis is recommended, preferably
with pdC1-INH, before chorionic villus sampling, amniocen-
tesis, and induced surgical abortion. Alternatively, pdC1-INH
should be available and administered immediately at the onset
of edema. It is recommended to manage childbirth in the
hospital setting. Routine administration of short-term pro-
phylaxis before uncomplicated natural delivery is not recom-
mended, but pdC1-INH should be immediately available for
on-demand use. Administering pdC1-INH is recommended
before labor and delivery when HAE is severe, if symptoms
have been recurring frequently during the third trimester,
if the patient’s history includes genital edema caused by
mechanical trauma, when intubation is required, and when
forceps delivery or vacuum extraction is performed. Short-
term prophylaxes with pdC1-INH and epidural anesthesia are
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and intubation should be avoided if possible.
39,43,46,76,114
If long-term prophylaxis is required during pregnancy,
then pdC1-INH is considered a safe and effective treatment
option. Antiﬁbrinolytics may be used only when pdC1-INH is
unavailable. They should be used only if clearly needed and if
the potential beneﬁt justiﬁes the potential risk to the fetus,
especially because evidence for the efﬁcacy of the product is
lacking.
Androgens are not recommended, as these drugs cross
the placenta. Their adverse effects include masculinization of
the female fetus, placental insufﬁciency, and fetal growth
retardation. Breast-feeding should be discontinued before
androgens are introduced: terminating lactation itself may
reduce attack frequency.
pdC1-INH is considered the best therapy for on-
demand treatment, short-term prophylaxis and long-term
prophylaxis when indicated during lactation. Androgens
and antiﬁbrinolytics should be avoided because they are
secreted in breast milk. SDP may be used for short-term
prophylaxis and on-demand therapy but is not as safe as
C1-INH and is a second-line agent because of the greater
risk of viral transmission and the possibility of worsening
an attack.
39,43,46,76,114,123
PATIENT SUPPORT, HOME THERAPY AND
SELF-ADMINISTRATION, AND OTHER
MANAGEMENT CONSIDERATIONS
Patient Support
Patient organizations and support groups provide help
and support for HAE patients and caregivers and endorse the
philosophy that all patients should have the resources to
control their HAE symptoms and fulﬁll their potential at
school, at work, and in their relationships. HAEi, the
International Patient Organization for C1 Inhibitor Deﬁcien-
cies, and national HAE associations have active informative
Web sites for patients and health care providers. HAEi has
launched a “call to action” aimed at increasing the awareness
and knowledge on HAE with governments, health authorities,
and health care professionals and to achieve recognition of
HAE as a serious, disabling, potentially life-threatening, and
chronic condition that must receive timely accurate diagnosis
and effective treatment.
Patient organizations also work toward identifying
and addressing unmet needs in HAE management, which
include the development of safe and well-tolerated oral
prophylactic and on-demand therapies, the optimization of
existing long-term prophylactic and on-demand therapies
(eg, by dose-ranging studies, subcutaneous prophylaxis,
pediatric studies, head-to-head studies), cost/effectiveness
studies, increasing the availability of modern treatment
options worldwide, emphasizing the need for self-care,
individual action plans, early therapy, and gene therapy
research. As with most diseases, information on Web sites
can be questionable; however, HAEi provides reviewed,
updated, and reliable information and is considered to be
a quality source for patient education.
47
Individualized Patient Action and
Treatment Plans
Recommendation 15
All patients with HAE should have an action plan
and product available to treat an attack of HAE. Evidence
grade: D, strength of recommendation: strong.
Because HAE-1/2 is an unpredictable, painful, and life-
threatening condition that places a huge stressful burden on
patients and their families, an individualized treatment plan
should be carefully developed in partnership between the
physician and the patient. Individualized treatment plans
should address preventive measures and home care and self-
administration and include an emergency (on demand) treat-
ment plan. Patients should carry on-demand medication and an
HAE identiﬁcation card with instructions on how to use the
on-demand medication in case of an attack. Patients on long-
term prophylaxis, with either C1-INH or androgens, also
require a acute care plan and therapy for on-demand use.
46,76
Home Therapy and Self-administration
Recommendation 16
We recommend that all patients who are provided
with on-demand treatment licensed for self-administration
should be taught to self-administer. Evidence grade: D,
strength of recommendation: strong.
Recommendation 17
We recommend that all patients should be provided
with an HAE identiﬁcation card. Evidence grade: D,
strength of recommendation: strong.
Every patient with HAE-1/2 should be considered for
home therapy and self-administration, once the diagnosis is
conﬁrmed. Requirement to attend a medical facility may result in
delayed on-demand treatment, inappropriate therapy, and many
attacks are not treated at all. This contributes to the morbidity and
social and economic disadvantage associated with HAE. All
patients should therefore be considered for self-administration
training with either C1-INH or icatibant. In the United States,
ecallantide can be given at home by a health care provider trained
to treat anaphylaxis. Self-administration training should include
the training of a “home therapy partner” (a family member or
friend who can provide support, advice, and administration of
therapy when the patient is compromised or unable or uncomfort-
able with self-treatment).
47,84,132–136
Patients undertaking travel and patients living alone
may experience particular difﬁculty in obtaining on-demand
treatment administered by a physician, and they may,
therefore, be more likely to present late or to leave severe
attacks untreated if unable to self-administer. These patient
groups are likely to gain the greatest beneﬁt from the ability to
control attacks by self-administration.
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decreases the severity and duration of attacks, reduces
morbidity and disability of attacks, and can improve quality
of life and productivity. In addition, the cost of care is reduced
considerably by the use of home and self-therapy.
137,138
C1-INH home therapy is suitable for children with
frequent or disruptive attacks, where a responsible adult is
available and willing to undertake training. Experience with
hemophilia suggests that it is beneﬁcial for children to be
encouraged to take an active part early in their treatment, and
even at the age of 8, self-administration is possible and safe.
135
Advanced age is not a contraindication for home
therapy, provided that patients and home therapy partners
can safely and effectively administer treatment. Also, pdC1-
INH home therapy seems safe and effective and is recom-
mended for prophylaxis or treatment of pregnant and lactating
women. In contrast, long-term prophylaxis with attenuated
androgens or TA is not recommended in pregnancy. Therefore,
self-administration of pdC1-INH should be considered for
control of symptoms for pregnant and lactating women.
Women with HAE contemplating pregnancy should consider
home self-administration training.
87,114,128,139
With self-administration or home administration, it is
extremely important to encourage all patients to seek care
after administration of therapy for an upper airway attack.
With all therapies, upper airway swelling may progress or
rebound and repeat dosing may be necessary. Seeking
emergency care after therapy is essential to reduce the risk
of death associated with airway swelling.
Avoidance of Triggers
A variety of conditions and events are known to trigger
swelling attacks. Trauma, whether accidental or associated
with dental, medical, and surgical procedures, commonly
results in a swelling attack. The use of estrogen-containing
oral contraceptive agents and hormone replacement therapy
and antihypertensive agents containing ACE inhibitors may
increase the frequency or precipitate an HAE attack. Other
reported triggers include psychological stress, fatigue, febrile
illness, alcohol, possibly Helicobacter pylori infection, and
the menstrual cycle. Patients should be made aware of poten-
tially relevant triggers of attack to reduce precipitation of
attacks. Inﬂuenza vaccine may reduce upper airway infections
and possibly reduce upper airway swelling. Hepatitis vaccines
may reduce the risk of viral transmission that can be associated
with exposure to blood products. Good dental care can reduce
extractions, need for aggressive dental procedures, and prevent
acute or chronic intraoral inﬂammation, which might reduce
the threshold for attacks. Monitoring for side effects of medi-
cations is important and is outlined above.
22,39,43,45,140,141
Expert Involvement and Checkups
Recommendation 18
All patients with HAE should have at least 1 annual
assessment by an HAE specialist. Evidence grade: D,
strength of recommendation: strong.
TABLE 2. Procedures Recommended During Long-term Care
for HAE Patients
Procedures Timing
Develop action plan When diagnosed and
reviewed annually
Provide with HAE emergency
card
When diagnosed and
reviewed annually
Provide with 2 doses of on
demand therapy
When diagnosed
Screen family When diagnosed
Hepatitis C, B and HIV
screening
When diagnosed and annually
if receiving blood products
Hepatitis A and B vaccine When diagnosed
Assessment by an HAE
specialist
Annually
Inﬂuenza vaccine Annually
If long-term androgens are
used
LFT, CBC, LP, UA At start and every 6 mo
Assess cardiac risk factors At start and every 6 mo
Ultrasound liver At start and every 12 mo
CBC, complete blood count; HIV, human immunodeﬁciency virus; LFT, liver
function tests; LP, lipid proﬁle; UA, urine analysis.
TABLE 3. First-Line Options for On-Demand Treatment of HAE-1/2
Route of
administration Efﬁcacy Safety Limitation
Self-
administration Age, yrs Cost
Berinert IV 111 111* 1† 1 All ($12 in the
United States)
High
Cinryze IV 111 111* 1† 1 $12 High
Ruconest IV 111 111 1‡ 2 $18 High
Icatibant SC 111 111 1§ 1 $18 High
Ecallantide SC 111 111 1|| 2. 16 High
IV, intraveneous; SC, subcutaneous.
*Blood product.
†Pretreatment vaccination recommended.
‡Pretreatment and repeated allergological testing required.
§Special attention required in acute ischemic heart disease/unstable angina and in the ﬁrst week after cerebral infarction.
¶Three injections.
||Posttreatment observation/keep refrigerated.
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ﬁnd a health care provider with knowledge and interest in the
disease. When and where possible, care should be provided
by comprehensive care clinics with expertise in HAE.
It is recommended that HAE patients have a medical
evaluation at least annually. Newly diagnosed patients and
those on long-term prophylaxis with attenuated androgens
should be seen at 3-month intervals initially and then twice
a year for 2 years. Those on androgens should continue to be
seen twice a year. Evaluation at follow-up visits should
include recording of type and frequency and severity of
symptoms, frequency of use, and effectiveness of treatments
for swelling attacks. A physical examination and appropriate
laboratory evaluation should be conducted (Table 2).
39,43,45
Family Screening
Recommendation 19
Family members of patients with HAE should be
screened so that appropriate therapy can be available for
treatment, especially because the ﬁrst event may be of the
upper airway and fatal without appropriate therapy.
Evidence grade: D, strength of recommendation: strong.
HAE-1/2 is a genetic disorder with autosomal dominant
transmission. Family members including grandparents,
parents, siblings, children, and grandchildren of HAE-1/2
patients should be screened for C4, C1-INH level, and
C1-INH functional plasma levels.
46,69,76
If these values are normal in family members with
unexplained abdominal pain or angioedema, then these tests
should be repeated at the time a swelling attack occurs.
39,43,45
Vaccinations
Recommendation 20
Hepatitis A and B vaccination should be adminis-
tered to HAE-1/2 patients receiving blood products,
including pdC1-INH. All patients should receive inﬂuenza
vaccine. Evidence grade: D, strength of recommendation:
strong.
All HAE patients have a potential for receiving human
blood products. Because of this, HAE patients should be
screened as early as possible for hepatitis B and C and HIV.
Vaccination for hepatitis A and B reduces the risk of
infections and the use of blood products including pdC1-
INH that bears a theoretical risk of pathogen transmission.
Annual assessment for infections with hepatitis B, C, and
HIV is suggested.
46,69,76
ACKNOWLEDGMENTS
The authors would like to thank Kerri Landis, Amanda
Hegg and Beate Schinzel for their time, efforts and insight in
making the Guideline a success.
REFERENCES
1. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, et al.
Grading quality of evidence and strength of recommendations in clinical
practice guidelines. Part 1 of 3. An overview of the GRADE approach and
grading quality of evidence about interventions. Allergy. 2009;64:669–677.
2. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H,
Reshef A, Zuraw B. Evidence-based recommendations for the therapeu-
tic management of angioedema owing to hereditary C1 inhibitor deﬁ-
ciency: consensus report of an International Working Group. Allergy.
2012;67:147–157.
3. Munch EP, Weeke B. Non-hereditary angioedema treated with tranexa-
mic acid. A 6-month placebo controlled trial with follow-up 4 years
later. Allergy. 1985;40:92–97.
4. Lewis JH. Idiopathic gastric acid hypersecretion: treatment implications
for refractory acid/peptic disorders. Aliment Pharmacol Ther. 1991;
5(suppl 1):15–24.
5. Gluszko P, Undas A, Amenta S, Szczeklik A, Schmaier AH. Adminis-
tration of gamma interferon in human subjects decreases plasminogen
activation and ﬁbrinolysis without inﬂuencing C1 inhibitor. J Lab Clin
Med. 1994;123:232–240.
6. Cicardi M, Mannucci PM, Castelli R, Rumi MG, Agostoni A. Reduction
in transmission of hepatitis C after the introduction of a heat-treatment
step in the production of C1-inhibitor concentrate. Transfusion. 1995;
35:209–212.
7. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema
with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334:
1630–1634.
8. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-
term prophylaxis with attenuated androgens in hereditary angioedema:
comparison of treated and untreated patients. J Allergy Clin Immunol.
1997;99:194–196.
9. Goring HD, Bork K, Späth PJ, Bauer R, Ziemer A, Hintner H,
Wüthrich B. Hereditary angioedema in the German-speaking region
[in German]. Hautarzt. 1998;49:114–122.
10. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G,
Schwarz HP. A randomized, controlled trial to study the efﬁcacy and
safety of C1 inhibitor concentrate in treating hereditary angioedema.
Transfusion. 1998;38:540–549.
11. Farkas H, Gyeney L, Gidófalvy E, Füst G, Varga L. The efﬁcacy of
short-term danazol prophylaxis in hereditary angioedema patients
undergoing maxillofacial and dental procedures. J Oral Maxillofac
Surg. 1999;57:404–408.
12. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema
with C1 inhibitor concentrate in patients with hereditary angioedema.
Arch Intern Med. 2001;161:714–718.
13. Gompels MM, Lock RJ, Gidófalvy E, Füst G, Varga L. A multicentre
evaluation of the diagnostic efﬁciency of serological investigations for
C1 inhibitor deﬁciency. J Clin Pathol. 2002;55:145–147.
14. Weiler JM, Quinn SA, Woodworth GG, Brown DD, Layton TA,
Maves KK. Does heparin prophylaxis prevent exacerbations of hered-
itary angioedema? J Allergy Clin Immunol. 2002;109:995–1000.
15. Szeplaki G, Varga L, Valentin S, Kleiber M, Karádi I. Adverse effects
of danazol prophylaxis on the lipid proﬁles of patients with hereditary
angioedema. J Allergy Clin Immunol. 2005;115:864–869.
16. van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, et al.
A phase I study of recombinant human C1 inhibitor in asymptomatic patients
with hereditary angioedema. J Allergy Clin Immunol. 2005;116:876–883.
17. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacother-
apy of acute hereditary angioedema with bradykinin B2-receptor antag-
onist icatibant. Allergy. 2006;61:1490–1492.
18. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W.
Treatment of acute edema attacks in hereditary angioedema with a bra-
dykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol.
2007;119:1497–1503.
19. Ott HW, Mattle V, Hadziomerovic D, Licht P, Döinghaus K, et al.
Treatment of hereditary angioneurotic oedema (HANE) with tibolone.
Clin Endocrinol (Oxf). 2007;66:180–184.
20. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical
role of kallikrein in hereditary angioedema pathogenesis: a clinical trial
of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol.
2007;120:416–422.
Craig, et al WAO Journal   December 2012
196  2012 World Allergy Organization21. Varga L, Biro A, Széplaki G, Tóth L, Horváth A, Füst G, Farkas H.
Anti-cholesterol antibody levels in hereditary angioedema. J Cell Mol
Med. 2007;11:1377–1383.
22. Visy B, Fust G, Bygum A, Bork K, Longhurst H, et al. Helicobacter
pylori infection as a triggering factor of attacks in patients with hered-
itary angioedema. Helicobacter. 2007;12:251–257.
23. Birjmohun RS, Kees Hovingh G, Stroes ES, Hofstra JJ, Dallinga-
Thie GM, et al. Effects of short-term and long-term danazol treatment
on lipoproteins, coagulation, and progression of atherosclerosis: two
clinical trials in healthy volunteers and patients with hereditary angioe-
dema. Clin Ther. 2008;30:2314–2323.
24. Cedzynski M, Madalinski K, Gregorek H, Swierzko AS, Nowicka E,
et al. Possible disease-modifying factors: the mannan-binding lectin
pathway and infections in hereditary angioedema of children and adults.
Arch Immunol Ther Exp (Warsz). 2008;56:69–75.
25. Szegedi R, Szeplaki G, Varga L, Prohászka Z, Széplaki Z, et al. Long-
term danazol prophylaxis does not lead to increased carotid intima-
media thickness in hereditary angioedema patients. Atherosclerosis.
2008;198:184–191.
26. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, et al.
Efﬁcacy of human C1 esterase inhibitor concentrate compared with
placebo in acute hereditary angioedema attacks. J Allergy Clin Immu-
nol. 2009;124:801–808.
27. Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C,
Klingebiel T. C1-inhibitor concentrate for individual replacement ther-
apy in patients with severe hereditary angioedema refractory to danazol
prophylaxis. Transfusion. 2009;49:1987–1995.
28. Bas M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK, Kojda G.
Therapeutic efﬁcacy of icatibant in angioedema induced by angiotensin-
converting enzyme inhibitors: a case series. Ann Emerg Med. 2010;56:
278–282.
29. Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, et al.
Population pharmacokinetics of plasma-derived C1 esterase inhibitor
concentrate used to treat acute hereditary angioedema attacks. Ann
Allergy Asthma Immunol. 2010;105:149–154.
30. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, et al.
Icatibant, a new bradykinin-receptor antagonist, in hereditary angio-
edema. N Engl J Med. 2010;363:532–541.
31. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, et al. Ecallantide
for the treatment of acute attacks in hereditary angioedema. N Engl J
Med. 2010;363:523–531.
32. Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, et al.
Prospective study of rapid relief provided by C1 esterase inhibitor in
emergency treatment of acute laryngeal attacks in hereditary angioede-
ma. J Clin Immunol. 2010;30:823–829.
33. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT,
Pullman WE. EDEMA4: a phase 3, double-blind study of subcutaneous
ecallantide treatment for acute attacks of hereditary angioedema. Ann
Allergy Asthma Immunol. 2010;104:523–529.
34. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, et al. Recombinant
human C1-inhibitor for the treatment of acute angioedema attacks in
patients with hereditary angioedema. J Allergy Clin Immunol.
2010;126:821–827.e814.
35. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, et al. Nanoﬁltered
C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl
J Med. 2010;363:513–522.
36. Bissler JJ, Donaldson VH, Davis AE 3rd. Contiguous deletion and
duplication mutations resulting in type 1 hereditary angioneurotic
edema. Hum Genet. 1994;93:265–269.
37. Zhang Y, Dipple KM, Vilain E, Huang BL, Finlayson G, et al. AluY
insertion (IVS4-52ins316alu) in the glycerol kinase gene from an individ-
ual with benign glycerol kinase deﬁciency. Hum Mutat. 2000;15:316–323.
38. Bowen T, Hebert J, Ritchie B, Burnham J, MacSween M, et al. Man-
agement of hereditary angioedema: a Canadian approach. Transfus
Apher Sci. 2003;29:205–214.
39. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, et al. Canadian 2003
International Consensus Algorithm For the Diagnosis, Therapy, and
Management of Hereditary Angioedema. J Allergy Clin Immunol.
2004;114:629–637.
40. Bracho FA. Hereditary angioedema. Curr Opin Hematol. 2005;12:493–498.
41. Chinen J, Shearer WT. Basic and clinical immunology. J Allergy Clin
Immunol. 2005;116:411–418.
42. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, et al. C1
inhibitor deﬁciency: consensus document. Clin Exp Immunol.
2005;139:379–394.
43. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, et al. Hereditary
angiodema: a current state-of-the-art review, VII: Canadian Hungarian
2007 International Consensus Algorithm for the Diagnosis, Therapy,
and Management of Hereditary Angioedema. Ann Allergy Asthma
Immunol. 2008;100(suppl 2):S30–S40.
44. Bowen T. Hereditary angioedema consensus 2010. Allergy Asthma Clin
Immunol. 2010;6:13.
45. Bowen T, Brosz J, Brosz K, Hebert J, Ritchie B. Management of
hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin
Immunol. 2010;6:20.
46. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, et al. 2010
International consensus algorithm for the diagnosis, therapy and man-
agement of hereditary angioedema. Allergy Asthma Clin Immunol.
2010;6:24.
47. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, et al.
HAE international home therapy consensus document. Allergy Asthma
Clin Immunol. 2010;6:22.
48. Dinkelacker E. Ueber acutes Oedem [dissertation]. Kiel, Germany:
Unversity of Kiel; 1882.
49. Rosen FS, Austen KF. The “neurotic edema” (hereditary angioedema).
N Engl J Med. 1969;280:1356–1357.
50. Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A,
Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am J
Med Sci. 1982;284:2–9.
51. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new
ﬁndings concerning symptoms, affected organs, and course. Am J Med.
2006;119:267–274.
52. Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations
and treatment. Br J Hosp Med (Lond). 2006;67:654–657.
53. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol.
2005;53:373–388; quiz 389–392.
54. Seidman MD, Lewandowski CA, Sarpa JR, Potesta E, Schweitzer VG.
Angioedema related to angiotensin-converting enzyme inhibitors.
Otolaryngol Head Neck Surg. 1990;102:727–731.
55. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A.
Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–1697.
56. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffré D, Nussberger J.
Angioedema due to angiotensin-converting enzyme inhibitors. Immu-
nopharmacology. 1999;44:21–25.
57. Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneur-
otic edema: two genetic variants. Science. 1965;148:957–958.
58. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López-
Trascasa M. Hereditary angioedema due to C1 inhibitor deﬁciency:
patient registry and approach to the prevalence in Spain. Ann Allergy
Asthma Immunol. 2005;94:498–503.
59. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey.
Br J Dermatol. 2009;161:1153–1158.
60. Donaldson VH, Rosen FS. Action of complement in hereditary angio-
neurotic edema: the role of C’1-esterase. J Clin Invest. 1964;43:
2204–2213.
61. Donaldson VH, Rosen FS, Bing DH. Kinin generation in hereditary
angioneurotic edema (H.A.N.E.) plasma. Adv Exp Med Biol. 1983;156:
183–191.
62. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin forma-
tion and inﬂammatory disease. J Allergy Clin Immunol. 2002;109:
195–209.
63. Donaldson VH. Kinin formation in hereditary angioneurotic edema
(HANE) plasma. Int Arch Allergy Appl Immunol. 1973;45:206–209.
64. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary
angioedema plasma: evidence against kinin derivation from C2 and in
support of “spontaneous” formation of bradykinin. J Allergy Clin
Immunol. 1983;72:54–60.
65. Maurer M, Bader M, Bas M, Bossi F, Cicardi M, et al. New topics in
bradykinin research. Allergy. 2011;66:1397–1406.
66. Binkley KE, Davis A III. Clinical, biochemical, and genetic character-
ization of a novel estrogen-dependent inherited form of angioedema.
J Allergy Clin Immunol. 2000;106:546–550.
67. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with
normal C1-inhibitor activity in women. Lancet. 2000;356:213–217.
WAO Journal   December 2012 Hereditary Angioedema WAO Guideline
 2012 World Allergy Organization 19768. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1
inhibitor in a family with affected women and men. Br J Dermatol.
2006;154:542–545.
69. Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, et al.
Consensus statement on the diagnosis, management, and treatment of
angioedema mediated by bradykinin. Part I. Classiﬁcation, epidemiology,
pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig
Allergol Clin Immunol. 2011;21:333–347; quiz follow 347.
70. Karim Y, Grifﬁths H, Deacock S. Normal complement C4 values do not
exclude hereditary angioedema. J Clin Pathol. 2004;57:213–214.
71. Tarzi MD, Hickey A, Förster T, Mohammadi M, Longhurst HJ. An
evaluation of tests used for the diagnosis and monitoring of C1 inhibitor
deﬁciency: normal serum C4 does not exclude hereditary angio-oedema.
Clin Exp Immunol. 2007;149:513–516.
72. Wagenaar-Bos IG, Drouet C, Aygören-Pursun E, Bork K, Bucher C,
et al. Functional C1-inhibitor diagnostics in hereditary angioedema:
assay evaluation and recommendations. J Immunol Methods. 2008;
338:14–20.
73. Zuraw BL. Diagnosis and management of hereditary angioedema: an
American approach. Transfus Apher Sci. 2003;29:239–245.
74. Bork K. Hereditary angioedema with normal C1 inhibitor activity
including hereditary angioedema with coagulation factor XII gene
mutations. Immunol Allergy Clin North Am. 2006;26:709–724.
75. Weiler CR, van Dellen RG. Genetic test indications and interpretations
in patients with hereditary angioedema. Mayo Clin Proc. 2006;81:
958–972.
76. Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, et al.
Consensus statement on the diagnosis, management, and treatment of
angioedema mediated by bradykinin. Part II. Treatment, follow-up, and
special situations. J Investig Allergol Clin Immunol. 2011;21:422–441;
quiz 442–423.
77. Temino VM, Peebles RS Jr. The spectrum and treatment of angioedema.
Am J Med. 2008;121:282–286.
78. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G,
Church MK, et al. EAACI/GA(2)LEN/EDF/WAO guideline: manage-
ment of urticaria. Allergy. 2009;64:1427–1443.
79. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema
caused by missense mutations in the factor XII gene: clinical features,
trigger factors, and therapy. J Allergy Clin Immunol. 2009;124:129–134.
80. Farkas H, Szongoth M, Kaposi PN, Karádi I, Fekete B, et al. Angiooe-
dema due to acquired deﬁciency of C1-esterase inhibitor associated with
leucocytoclastic vasculitis. Acta Derm Venereol. 2001;81:298–300.
81. Kaplan AP. C1 inhibitor deﬁciency: hereditary and acquired forms.
J Investig Allergol Clin Immunol. 2001;11:211–219.
82. Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-
inhibitor deﬁciency: a bridging condition between autoimmunity and
lymphoproliferation. Autoimmun Rev. 2008;8:156–159.
83. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor
concentrate in patients with hereditary or acquired angioedema caused by
C1-inhibitor deﬁciency. J Allergy Clin Immunol. 2006;117:904–908.
84. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intra-
venous C1-inhibitor therapy for hereditary angioedema and associated
quality of life beneﬁts. Eur J Dermatol. 2009;19:147–151.
85. Gras J. Icatibant for hereditary angioedema. Drugs Today (Barc).
2009;45:855–864.
86. Bork K. Recurrent angioedema and the threat of asphyxiation. Dtsch
Arztebl Int. 2010;107:408–414.
87. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, Heller C,
Klingebiel T, Kreuz W. Characterization of acute hereditary angioede-
ma attacks during pregnancy and breast-feeding and their treatment
with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203:131.
e1–e7.
88. Groner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase
inhibitor concentrate. Transfusion. 2012;52:2104–2112.
89. Ärzteschaft A. Schwerwiegende Thrombenbildung nach Berinert HS.
Deutsches Ärzteblatt. 2000;97:A-1016.
90. Bork K, Hardt J. Hereditary angioedema: increased number of attacks
after frequent treatments with C1 inhibitor concentrate. Am J Med.
2009;122:780–783.
91. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one
or more injections of C1 inhibitor concentrate per week. Int Arch
Allergy Immunol. 2011;154:81–88.
92. Varga L, Farkas H. Treatment of type I and II hereditary angioedema
with Rhucin, a recombinant human C1 inhibitor. Expert Rev Clin
Immunol. 2008;4:653–661.
93. Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE.
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated
analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol.
2011;128:153–159.e154.
94. Bygum A, Broesby-Olsen S. Rapid resolution of erythema marginatum
after icatibant in acquired angioedema. Acta Derm Venereol. 2011;91:
185–186.
95. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema
and facial swellings after tooth extraction in patients with hereditary
angioedema with and without prophylaxis with C1 inhibitor concen-
trate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2011;112:58–64.
96. Zuraw BL. Hereditary angiodema: a current state-of-the-art review, IV:
short- and long-term treatment of hereditary angioedema: out with
the old and in with the new? Ann Allergy Asthma Immunol. 2008;
100(suppl 2):S13–S18.
97. Maurer M, Magerl M. Hereditary angioedema: an update on available
therapeutic options. J Dtsch Dermatol Ges. 2010;8:663–672.
98. Van Sickels NJ, Hunsaker RB, Van Sickels JE. Hereditary angioede-
ma: treatment, management, and precautions in patients presenting for
dental care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2010;109:168–172.
99. Gompels MM, Lock RJ. Cinryze (C1-inhibitor) for the treatment of
hereditary angioedema. Expert Rev Clin Immunol. 2011;7:569–573.
100. Lunn M, Santos C, Craig T. Cinryze as the ﬁrst approved C1 inhibitor
in the USA for the treatment of hereditary angioedema: approval, efﬁ-
cacy and safety. J Blood Med. 2010;1:163–170.
101. Tallroth GA. Long-term prophylaxis of hereditary angioedema with
a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol.
2011;154:356–359.
102. Blackmore WP. Danazol in the treatment of hereditary angio-neurotic
oedema. J Int Med Res. 1977;5(suppl 3):38–43.
103. Agostoni A, Cicardi M, Martignoni GC, Bergamaschini L, Marasini B.
Danazol and stanozolol in long-term prophylactic treatment of hereditary
angioedema. J Allergy Clin Immunol. 1980;65:75–79.
104. Wharton JG. Hereditary angioedema: response to danazol. Practitioner.
1982;226:935–936.
105. Zurlo JJ, Frank MM. The long-term safety of danazol in women with
hereditary angioedema. Fertil Steril. 1990;54:64–72.
106. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G,
Agostoni A. Long-term treatment of hereditary angioedema with atten-
uated androgens: a survey of a 13-year experience. J Allergy Clin
Immunol. 1991;87:768–773.
107. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in
patients with hereditary angio-oedema. J Hepatol. 2002;36:707–709.
108. Bork K, Bygum A, Hardt J. Beneﬁts and risks of danazol in hereditary
angioedema: a long-term survey of 118 patients. Ann Allergy Asthma
Immunol. 2008;100:153–161.
109. Farkas H, Czaller I, Csuka D, Vas A, Valentin S, et al. The effect of long-
term danazol prophylaxis on liver function in hereditary angioedemada
longitudinal study. Eur J Clin Pharmacol. 2010;66:419–426.
110. Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema
with androgen derivates: a critical appraisal and potential alternatives.
J Dtsch Dermatol Ges. 2011;9:99–107.
111. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hered-
itary angioneurotic edema. N Engl J Med. 1972;287:452–454.
112. Crosher R. Intravenous tranexamic acid in the management of heredi-
tary angio-oedema. Br J Oral Maxillofac Surg. 1987;25:500–506.
113. Farkas H, Harmat G, Füst G, Varga L, Visy B. Clinical management of
hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002;
13:153–161.
114. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, et al. Interna-
tional consensus and practical guidelines on the gynecologic and obstet-
ric management of female patients with hereditary angioedema caused
by C1 inhibitor deﬁciency. J Allergy Clin Immunol. 2012;129:308–320.
115. Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children:
a management guideline. Pediatr Allergy Immunol. 2005;16:288–294.
116. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deﬁ-
ciency. Allergy Asthma Clin Immunol. 2010;6:18.
Craig, et al WAO Journal   December 2012
198  2012 World Allergy Organization117. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, von Hentig N,
Klingebiel T, Kreuz W. Pharmacokinetic analysis of human plasma-derived
pasteurized C1-inhibitor concentrate in adults and children with hereditary
angioedema: a prospective study. Transfusion. 2010;50:354–360.
118. Caballero T. Angio-oedema due to hereditary C1 inhibitor deﬁciency in
children. Allergol Immunopathol (Madr). 2012.
119. Kjaer L, Bygum A. Hereditary angioedema in childhood: a challenging
diagnosis you cannot afford to miss. Pediatr Dermatol. 2012.
120. Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy:
age related changes. Pediatr Res. 1979;13:1043–1046.
121. Roach B, Kim Y, Jerome E, Michael AF. Inﬂuence of age and sex on
serum complement components in children. Am J Dis Child. 1981;135:
918–920.
122. Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and
diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35:
184–187.
123. Wahn V, Aberer W, Eberl W, Faßhauer M, Kühne T, et al. Hereditary
angioedema (HAE) in children and adolescentsda consensus on ther-
apeutic strategies. Eur J Pediatr. 2012;171:1339–1348.
124. Yip J, Cunliffe WJ. Hormonally exacerbated hereditary angioedema.
Australas J Dermatol. 1992;33:35–38.
125. Visy B, Fust G, Varga L, Szendei G, Takács E, et al. Sex hormones
in hereditary angioneurotic oedema. Clin Endocrinol (Oxf). 2004;60:
508–515.
126. Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, et al.
Disease expression in women with hereditary angioedema. Am J Obstet
Gynecol. 2008;199:484.e1–e4.
127. Cox M, Holdcroft A. Hereditary angioneurotic oedema: current man-
agement in pregnancy. Anaesthesia. 1995;50:547–549.
128. Duvvur S, Khan F, Powell K. Hereditary angioedema and pregnancy.
J Matern Fetal Neonatal Med. 2007;20:563–565.
129. Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin
Immunol. 2010;6:17.
130. Czaller I, Visy B, Csuka D, Füst G, Tóth F, Farkas H. The natural
history of hereditary angioedema and the impact of treatment with
human C1-inhibitor concentrate during pregnancy: a long-term survey.
Eur J Obstet Gynecol Reprod Biol. 2010;152:44–49.
131. Montinaro V, Castellano G. Management of pregnancy and vaginal
delivery by C1 inhibitor concentrate in two hereditary angioedema
twins. Clin Immunol. 2010;136:456–457.
132. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy
for hereditary angioedema: a viable, effective treatment option. Clin Exp
Immunol. 2007;147:11–17.
133. Aygoren-Pursun E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W.
On demand treatment and home therapy of hereditary angioedema
in Germanydthe Frankfurt experience. Allergy Asthma Clin Immunol.
2010;6:21.
134. Farkas H, Csuka D, Zotter Z, Varga L, Böröcz Z, et al. Home treatment
of hereditary angioedema with icatibant administered by health care
professionals. J Allergy Clin Immunol. 2012;129:851–852.e2.
135. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C,
Klingebiel T. Home therapy with intravenous human C1-inhibitor in
children and adolescents with hereditary angioedema. Transfusion.
2012;52:100–107.
136. Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC,
Zuraw BL. Safety and efﬁcacy of physician-supervised self-managed c1
inhibitor replacement therapy. Int Arch Allergy Immunol. 2012;157:
417–424.
137. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE.
Economic costs associated with acute attacks and long-term manage-
ment of hereditary angioedema. Ann Allergy Asthma Immunol.
2010;104:314–320.
138. Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations
and emergency department visits with hereditary angioedema and angioe-
dema in the United States, 2007. Allergy Asthma Proc. 2010;31:511–519.
139. Gorman PJ. Hereditary angioedema and pregnancy: a successful out-
come using C1 esterase inhibitor concentrate. Can Fam Physician.
2008;54:365–366.
140. Farkas H, Fust G, Fekete B, Karádi I, Varga L. Eradication of Heli-
cobacter pylori and improvement of hereditary angioneurotic oedema.
Lancet. 2001;358:1695–1696.
141. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation
after tooth extraction in four patients with hereditary angioedema.
J Am Dent Assoc. 2003;134:1088–1094.
WAO Journal   December 2012 Hereditary Angioedema WAO Guideline
 2012 World Allergy Organization 199